NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Emergent BioSolutions Inc. (EBS) Stock Analysis

Emergent BioSolutions Inc. (EBS) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

EBS

$6.20

−$0.09 (−1.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EBS with… →

EBS Key Statistics

As of Oct 21, 2026
Trading
Open
$6.30
Previous Close
$6.29
Day's Range
6.15–6.38
52-Week Range
4.36–14.06
Volume
851.59K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.29
Valuation
Market Cap
$317.89M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
5.92
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.38
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.41
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.40
Financials (FY)
Revenue (FY)
$705.20M−30.43%
Net Income (FY)
$52.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
−22.96%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
51.27M
1-Year Return
−34.39%
Dividend and dates
Earnings Date
November 2, 2026
Avg Volume
1.20M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, EBS closed at $6.20, −34.39% over 1 year.

Emergent BioSolutions Inc. (EBS) has a market capitalization of $317.89M.

In fiscal 2025, EBS reported revenue of $705.20M.

EBS Stock Return by Calendar Year

Emergent BioSolutions Inc. (EBS) 10-year return: what $10,000 became

1 year
$10,000 $6,561
−34.39%
5 years
$10,000 $1,226
−87.74%
10 years
$10,000 $2,203
−77.97%

If you had invested $10,000 in Emergent BioSolutions Inc. (EBS) 10 years ago, at the close on October 21, 2016, it would have been worth $2,203 at the close on October 21, 2026: −77.97% in total, −14.04% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.84%
2025+29.29%
2024+298.33%
2023−79.68%
2022−72.83%
2021−51.48%
2020+66.08%
2019−8.99%
2018+27.57%
2017+41.50%
2016 (partial year)+10.31%

As of October 21, 2026.

EBS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$705.20M$52.60M7.5%
2024$1.01B−$190.60M−18.8%
2023$1.02B−$760.50M−74.3%
2022$1.08B−$211.60M−19.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$705.20M$379.00M$112.30M$52.60M7.5%
2024$1.01B$332.30M−$81.50M−$190.60M−18.8%
2023$1.02B$317.60M−$201.50M−$760.50M−74.3%
2022$1.08B$383.00M−$163.30M−$211.60M−19.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EBS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricEBSDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.412.100.2x the median
Profit margin−22.96%−8.14%14.8 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Emergent BioSolutions Inc. (EBS) carries a market capitalisation of $317.89M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 900 employees.

Over the past 52 weeks the price has ranged from $4.36 to $14.06. EBS last closed at $6.20 on October 21, 2026. That is −$0.09 (−1.43%) against the previous close. The latest close sits 42.2% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $705.20M. Against the prior fiscal year total of $1.01B, that is a change of −30.43%. Net income for the same year was $52.60M. Profit margin runs at −22.96%. That is 14.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −3.4.

Across the 4 fiscal years on file, revenue moves from $1.08B in 2022 to $705.20M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 5.92. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.38. The price-to-sales ratio is 0.41. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −34.39%. Across 10 years the annualized return works out at −14.04%. The reported beta is 2.29. Daily returns over the trailing 10 years annualize to a volatility of 80.68%.

Growth & Income

No dividend is on file for EBS.

2026 is still running; the total return is −49.84% year to date. The strongest complete calendar year on file is 2024 at +298.33%; the weakest is 2023 at −79.68%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Emergent BioSolutions Inc. (EBS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Emergent BioSolutions Inc. EBS $317.89M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Emergent BioSolutions Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Visit website →